284 filings
ARS
2023 FY
FGEN
FibroGen Inc
24 Apr 24
Annual report to shareholders
9:55pm
DEFA14A
FGEN
FibroGen Inc
24 Apr 24
Additional proxy soliciting materials
5:08pm
DEF 14A
FGEN
FibroGen Inc
Definitive proxy
24 Apr 24
5:01pm
10-K
2023 FY
FGEN
FibroGen Inc
Annual report
26 Feb 24
4:11pm
8-K
FGEN
FibroGen Inc
26 Feb 24
FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results
4:08pm
8-K
y1z7vp zwa6kx
6 Nov 23
FibroGen Reports Third Quarter 2023 Financial Results
4:05pm
8-K
g0egw9jwn76x 99ael
27 Oct 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:30pm
8-K
jdmgegl13z
5 Oct 23
Departure of Directors or Certain Officers
7:41pm
8-K
vnxsuxrt1u8gjkj7li98
6 Sep 23
Departure of Directors or Certain Officers
8:55am
8-K
3aqa18hmwz0 p74cvjsu
29 Aug 23
FibroGen Announces Topline Results from LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Ambulatory Duchenne Muscular Dystrophy
5:14pm
S-8
ytp0zi0d
7 Aug 23
Registration of securities for employees
4:22pm
8-K
dpa7p drieoa
7 Aug 23
FibroGen Reports Second Quarter 2023 Financial Results
4:06pm
8-K
37xk 7uoy1i3s8x
25 Jul 23
FibroGen Announces Leadership Transition
8:32am
8-K
cscbyuo9rtn88
19 Jul 23
Cost Associated with Exit or Disposal Activities
7:01am
8-K
u3ljycl 5xvwkio
26 Jun 23
FibroGen Announces Topline Results from Phase 3 ZEPHYRUS-1 Study of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis
9:05am
8-K
ock 2wfwh4
9 Jun 23
Submission of Matters to a Vote of Security Holders
4:05pm
8-K
zj4m4y5ipkchht89
7 Jun 23
FibroGen Announces Topline Results from LELANTOS-1 Phase 3 Clinical Study of Pamrevlumab in Non-Ambulatory Patients with Duchenne Muscular Dystrophy
9:00am
DEFA14A
fjfa3r9whdog4y5q2
31 May 23
Additional proxy soliciting materials
9:00am